Abstract
Background Timely genomic surveillance is required to inform public health responses to new SARS-CoV-2 variants. However, the processes involved in local genomic surveillance introduce inherent time constraints. The Regional Innovative Public Health Laboratory in Chicago developed and employed a genomic surveillance response playbook for the early detection and surveillance of emerging SARS-CoV-2 variants.
Methods The playbook outlines modifications to sampling strategies, laboratory workflows, and communication processes based on the emerging variant’s predicted viral characteristics, observed public health impact in other jurisdictions and local community risk level. The playbook outlines procedures for implementing and reporting enhanced and accelerated genomic surveillance, including supplementing whole genome sequencing (WGS) with variant screening by quantitative PCR (qPCR).
Results The ability of the playbook to improve the response to an emerging variant was tested for SARS-CoV-2 Omicron BA.1. Increased submission of clinical remnant samples from local hospital laboratories enabled detection of a new variant at 1% prevalence with 95% confidence rather than 2% at baseline. Genotyping qPCR concurred with WGS lineage assignments in 99.9% of 1541 samples with results by both methods, and was more sensitive, providing lineage results in 90.4% of 1833 samples rather than 85.1% for WGS, while reducing the time to lineage result from 27 to 7 days.
Conclusions The genomic surveillance response playbook provides a structured, stepwise, and data-driven approach to responding to emerging SARS-CoV-2 variants. These pre-defined processes can streamline workflows and expedite the detection and public health response to emerging variants. Based on the processes piloted during the Omicron BA.1 response, this method has been applied to subsequent Omicron subvariants and can be readily applied to future SARS-CoV-2 emerging variants and other public health surveillance activities.
Competing Interest Statement
MKH was a member of a clinical adjudication panel for an investigational SARS-CoV-2 vaccine produced by Sanofi.
Funding Statement
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $11,162,000 with 100 percent funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The project was determined to not meet the definition of human subjects research and was exempt from ethical approval by the Rush University Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The WGS datasets generated and/or analysed during the current study are available in GISAID, http://gisaid.org, under accession EPI_SET_230901ya. The qPCR datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
List of Abbreviations
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- WGS
- Whole genome sequencing
- PCR
- Polymerase chain reaction
- COVID-19
- Coronavirus disease 2019
- VOC
- Variant of concern
- RIPHL
- Regional Innovative Public Health Laboratory
- CDPH
- Chicago Department of Public Health
- RUMC
- Rush University Medical Center
- RT
- Reverse Transcription
- GISAID
- Global Initiative on Sharing All Influenza Data
- VOHC
- Variant of High Concern
- WHO
- World Health Organization
- MMWR
- Morbidity and Mortality Weekly Report week
- CI
- Confidence interval
